Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Managing Editor, Pharma Insights
UK
+12 year(s) experience
In Vivo
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
Scrip
Emerging Company Profile: With a new partner in Eli Lilly, Anima Biotech and its disruptive technology that controls protein translation is starting to make waves as it urges the industry to see the light.
Topic Clinical trials
Scrip
As the EMA lowers the flags of the 28 EU nations that have flown outside its London offices for 24 years, and prepares to moves its HQ to the Netherlands, Scrip takes a look at Europe’s new pharma regulatory hub.
Topic Business strategies Brexit
Scrip
Biochemist Greg Winter has scientifically contributed to some of the pharmaceutical industry's biggest commercial and therapeutic success stories. He tells Scrip how he feels about being labelled a pioneer and why he is still wary of the boardroom.
Topic Cancer
Scrip
ICON’s CEO Steve Cutler talks candidly about the impact of biotech funding, disruptive tech providers, and the constant pressure of running one of the industry’s largest CROs.
Topic Company analysis
Scrip
Although 10 of Japan’s largest pharma companies look set to add $11bn in revenues over the next nine years, a CAGR of only 1% reflects an expected $4.8bn in patent expiries, leaving Japanese pharma heads relying on innovation for the next phase of the region’s major wins.
Topic Business strategies
Scrip
Pharma has been busy making deals this year, while the political winds of change swirl overhead, as our infographic shows. Companies both big and small have been merging to carve out therapeutic niches, return value to shareholders, and position themselves for the next wave of innovation and change.
Topic Business strategies
Scrip
This year the Scrip 100 universe is bigger than ever. We have been tunneling into the 2015 full year financial data of 620 companies to continue the Scrip 100 series, and using this data we can see even more clearly the structure of a top-heavy industry.
Scrip
Where There's A Cure There's Controversy: Raymond Schinazi's Story
Topic Research
In Vivo
14 Nov 2019
Scrip
02 Jul 2019
Scrip
01 Jul 2019
Scrip
27 Jun 2019
Scrip
25 Jun 2019
Scrip
24 Jun 2019
Scrip
20 Jun 2019
Scrip
19 Jun 2019
Scrip
18 Jun 2019
Scrip
10 Jun 2019
Scrip
09 May 2019
Scrip
30 Apr 2019
Scrip
29 Apr 2019
Scrip
26 Apr 2019
Scrip
23 Apr 2019
